Icare USA Receives FDA Clearance for Icare HOME Tonometer

Source: Icare USA

Icare USA announced that the Icare HOME tonometer has been cleared by the FDA and is now available for use in the United States. The Icare HOME device, which received CE marking in 2014, allows eye care professionals to access added clinical data as their patients’ IOP fluctuates throughout the day.

“The fact that we can put a tonometer of this caliber in the hands of patients is truly unprecedented,” John Floyd, President and CEO of Icare USA, said in a company news release. “The Icare HOME makes doctors aware of dangerous spikes that they may never have known about otherwise. The impact and level of care that this provides cannot be overstated.”

The Icare HOME uses the same patented rebound technology that is used in other Icare tonometers, such as the ic100 and the TA01i. The Icare HOME unit requires no specialized skills for patient use.

Several features make the Icare HOME easy for patients to use, according to the company news release. For instance, the unit’s built-in Icare EyeSmart technology performs automatic OD/OS recognition. Positioning is also easy thanks to Icare EasyPos, which uses red and green light signals to help patients correctly position the tonometer. The Icare HOME also features Icare AMS, an automated measuring sequence that can take either a single measurement or a series of six measurements with one touch of a button.

The Icare HOME involves no puff of air and requires no drops. In the hands of patients, it is quick, effortless, and effective. For eye care professionals, the Icare HOME is designed to become a staple of care in the management of millions of patients who could benefit from additional IOP monitoring.

Related Content